download
TRANSCRIPT
![Page 2: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/2.jpg)
Outline
• Introduction
• Definition
• Causes
• Clinical evaluation
• Investigations
• Treatment
• Conclusion
![Page 3: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/3.jpg)
Introduction
![Page 4: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/4.jpg)
Gynecological,Endocrinological,Cosmetic &Psychogenic: {great anxiety, nature of the disease,
social acceptance}
![Page 5: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/5.jpg)
IncidenceNot knownMediterranean> AsianAmerican females: 10%European: 5%
![Page 6: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/6.jpg)
Cycle growth of hair
Several months 2 weeks 3 months
![Page 7: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/7.jpg)
Types of hairLanugo
Fetal hair
VellusShort,fine, UnpigmentedBefore puberty
TerminalLong, coarse, pigmented arises from vellus hair
![Page 8: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/8.jpg)
Non sexual Ambi-sexual Male sexual
Sites Lower parts of the scalp, eye brow, lashes, fore-arms, lower legs
Temporal & vertical parts of the scalp, axilla, lower pubic hair.
Ears, nasal tip, chin, sternum, upper pubic triangle, back.
Depend on Growth hormone from pituitary
Androgen in low concentration from the adrenals & ovaries in females & adrenals in male
Androgen in high concentration
Sites of hair
![Page 9: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/9.jpg)
Androgen production Androstenedione
Testosterone
Adrenal DHEA Ovary
DHEAS
50% 50%50%
25% 25%
90% 10%
100%
![Page 10: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/10.jpg)
Androgen in the blood
Male Normal female Hirsute female
Free 3% 1% 2%
Albumin 19% 19% 19%
SHBG 78% 80% 79%
![Page 11: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/11.jpg)
Androgen at target cell (hair follicle)Testosterone (T) 5œ-reductase. Dihydrtestosterone (DHT)
Androstanediol Glucuronide
3 alpha androstanediol glucuronide(3 alpha AG)
![Page 12: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/12.jpg)
Definitions
![Page 13: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/13.jpg)
Virilization: Defiminization: Atrophy of the breast & vaginaMusculinization: Hirsutism, deepening of voice, temporal balding. Increase size of the clitoris, muscular mass & libido
![Page 14: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/14.jpg)
Hirsutism: Latin hirsutus = shaggy, hairy
Excessive growth of terminal hair in male sexual sites. Excessive: Socially unacceptable to the patient F& G score >8
![Page 15: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/15.jpg)
Hypertrichosis Excessive growth ofLanugo, vellus or terminal hair in non-sexual sites (James et al, 2005)•CongAcquired•LocalizedGeneralized
Congenital hypertrichosis lanuginosa Drug-induced hypertrichosis
![Page 16: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/16.jpg)
Hirsutism:
•Not an increase in the number of hair follicles but an alteration in their character.
•An increase in the transformation of the vellus to terminal hair.
{Androgens will convert lanugo & vellus hair to terminal hair}.
![Page 17: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/17.jpg)
Hirsutism is a consequence of several
factors. An increase in: 1. Androgen production
2. The sensitivity of the androgen receptors at the level of the hair follicle.
3. The activity of 5œ-reductase.
![Page 18: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/18.jpg)
Causes
![Page 19: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/19.jpg)
A. Ovarian:.PCOS: 90% {hyperandrogenism, oligo-ovulation, PCO}
.Virilizing ovarian tumors {arrhenoblastoma, hilus cell tumor, lipod cell tumor, granulosa cell tumor}
.Luteoma of pregnancy { Not true tumor but an exaggerated reaction of ovarian stroma to chorionic gonadotropins. It is solid, usually unilateral & regress after labour}
.Ovarian dysgenesis
Turner’s syndrome
![Page 20: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/20.jpg)
B. Adrenal:•Cong adrenal hyperplasia•Tumors•Cushing syndrome
Congenital adrenal hyperplasia
![Page 21: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/21.jpg)
C. PERIPHERAL•Idiopathic: Regular ovulation & normal androgen levels•Insulin resistance– HAIRAN syndrome: HyperAndrogenicInsulin-Resistant Acanthosis Nigricans– 5H syndrome
acanthosis nigricans.
![Page 22: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/22.jpg)
•Aromatase deficiency•Glucocorticoid resistance•Hyperprolactinema can cause an increase in DHEAS. TT with bromocriptin: dec PRL & DHEAS
![Page 23: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/23.jpg)
Hirsutism
Anabolic steroids
Danazol
Metoclopramide
Methyldopa
Phenothiazines
Progestins
Reserpine
Testosterone
Hypertrichosis
Cyclosporine
Diazoxide
Hydrocortisone
Minoxidil
Penicillamine
Phenytoin
Psoralens
StreptomycinHunter, 2003
D. Drugs
![Page 24: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/24.jpg)
Clinical evaluation
![Page 25: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/25.jpg)
Primary objective: Confirm diagnosis Determine degreeExclude life threatening diseases
![Page 26: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/26.jpg)
History.Virilization, psychological.Onset & duration: Rapidly progressive virilization: androgen secreting tumors
.Menstrual history: PCOS, Pregnancy
.Family history: Hair patterns are similar in families
.Drug intake
![Page 27: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/27.jpg)
Examination.General: Thyroid disease, Cushing syndrome, Signs of virilization,Signs of insulin resistance e.g. acanthosis nigricans.
![Page 28: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/28.jpg)
.Breast: Galactorrhea {Hyperprolactinaemia can be accompanied by increase in adrenal androgen}
.Pelvic: mass
![Page 29: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/29.jpg)
Degree of hirsutism Photography or scoring systemsa. Ferriman & Gallwey(1961): 9 areas upper lip, chin, chestupper abdomen, lower abdomen, upper arm, thighs, upper back,lower back/buttocks
minimal=1, mild=2, moderate=3, severe=4
>8 = hirsutism
![Page 30: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/30.jpg)
Degree of hair growth (Ferriman & Gallwey,1961)
![Page 31: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/31.jpg)
![Page 32: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/32.jpg)
b. Macnight (1964): divided the body into 7 areas: FaceNeckShouldersChestAbdomenback
![Page 33: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/33.jpg)
Investigations
![Page 34: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/34.jpg)
Initial laboratory investigation(Speroph,2005)
1.Total testosterone: measures the ovarian & adrenal activity.2.17 OHP: an intermediate metabolite in steroidogensis in the adrenals. DHEAS: Good marker of Adrenal A productionNot essential
![Page 35: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/35.jpg)
•DHES is not essential (Speroff,2005)
1. If 17 OHP is normal: adrenal enzyme defect can be excluded .
2. Moderate elevations of DHES can be suppressed by suppression of ovulation.
3. DHES > 700 ug/dl is rare & is associated with high levels of T
4. Imaging of the adrenals is more cost-effective than measuring DHES.
![Page 36: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/36.jpg)
Testosterone (ng/dl)
>200 <200
U/S of the ovary Anovulation
(PRL, endom biopsy)
Adenxal mass Nothing
Laparotomy CT of the adrenala & ovaries
Laparotomy
![Page 37: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/37.jpg)
Free testosterone•Good correlation with total production rate (= secretion rate + peripheral conversion rate) Good correlation with degree of virilization•Free androgen index(FAI)= TX 100 / SHBG if > 4.5: PCOS•Not done routinely in presence of hirsutism
![Page 38: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/38.jpg)
3 alpha androstanediol glucuronide•Metabolite of DHT•Good marker of peripheral androgen action•Inc {increased activity of 5 alpha reductase} {end organ hypersensitivity}•Not done routinely:1. No change in diagnosis & treatment,2. Values overlap in 20%
![Page 39: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/39.jpg)
Ovarian tumors should be suspected
1. Rapid onset of virilization
2. Unilateral adenxal mass
3. Testosterone >200 ng/dl.
•TVS, CT or MRI.
![Page 40: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/40.jpg)
Screening for late onset adrenal hyperplasia•Incidence: 1-5%•Clinical indication of ACTH stimulation test:Strong family history Severe hirsutism from puberty Flatness of the breastHypertensionShort stature
![Page 41: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/41.jpg)
17 oh P(ng/dl) morning
< 200 > 200
Rules out adrenal hyperplasia ACTH stimulation test (0.25 21-hydroxylase deficiency mg ACTH I.V.& 17 oh P at time zero & after 1 hour)
Normal Abnormal
Rules out adrenal hyperplasia Adrenal hyperplasia
![Page 42: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/42.jpg)
Screening for Cushing syndrome•Rare•Indications: Centripetal obesity, buffalo humpMoon face, VirilizationPigmented stria, Hypertension
![Page 43: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/43.jpg)
Dexamethazone suppression test( 1 mg orally at bed time)
Free cortisol (ug/dl
> 6 < 6
long term dexamethazone test Normal
![Page 44: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/44.jpg)
PCOS TLH/FSH
usually inc2/1
Late-onset CAH 17-OH-P >200 ng/dL
Androgen-secreting ov tumor Total T >200 ng/dL
Androgen-secreting ad tumor DHEAS >700 g/dL
Cushing syndrome Cortisol Increased
Exogenous androgen use Toxicology screen
Increased
![Page 45: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/45.jpg)
Treatment
![Page 46: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/46.jpg)
I. General
II. Specific
III. Local
IV. Surgery
![Page 47: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/47.jpg)
I. General•Reassurance: •explain the condition, treatment regimen & the time required
•Stop smoking•Weight reduction: {Inc SHBG: Dec FT} Keep BMI around 21 kg / m2
Dec the risk of DM & CVD
![Page 48: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/48.jpg)
II. Specific
I. Ovarian suppression:
1. OCPs 2. Progestagen 3. GnRha
II. Adrenal suppression: Corticosteroids
III. Antiandrogens:
1. Spironolactone 2. Cyproterone acetate
3. Flutamide 4. Ketoconazole
IV. 5 alpha reductase inhibitors: Finasteride
V. Insulin sensitizer: Metformin
![Page 49: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/49.jpg)
I. Ovarian suppression: 1. Oral contraceptive pills
The first line of therapyMechanism: P: suppress ov steroidogenesis E: inc SHBG: dec FT
![Page 50: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/50.jpg)
Best type:Avoid OCs containing norethisterone or levonorgestrel less androgenic, high estrogenDiane (cyproterone acetate), Gynera (gestodene), Marvelon (desogestrel), Cilest (norgestimate).Effect: 1. Dec T after 1-3 mo. 2. Additional benefits
![Page 51: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/51.jpg)
2. ProgestinsIndication: If pills is contraindicated or unwanted Mechanism: inhibit ov steroidogenesis, inc clearance of androgen, inhibit 5 alpha reductasedec SHBG:inc FTDose: DMPA: 150 mg IM / 3 mo. MPA: 30 mg PO / dEffect: comparable to OCPs
![Page 52: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/52.jpg)
3. Gn Rh analogue Indications: Failure of usual managementOverweight with severe hirsutismDose: leuprolide acetate depot: IM / mo. The initial stimulatory effect can be avoided by starting therapy in the luteal phase when Gnt are already suppressed by elevated progesterone levels.Once maximal response has been obtained OCP or antiandrogen for long term suppression of hair growth.Treatment should be limited to 6 mo.
![Page 53: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/53.jpg)
Mechanism of action:Side effects: of estrogen deficiencyUse with OCPs: {avoid problems associated with E deficiency & add benefits}Effects: highly effective & better than OCP alone
![Page 54: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/54.jpg)
II. Adrenal suppression: GlucocorticoidsIndication: 1.High not moderate elevation of DHEAS (Sperof,2005)
2. CAHMechanism: inhibit ACTH dependant androgen
![Page 55: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/55.jpg)
Dose:Nocturnal {maximal suppression of the CNS adrenal axis that peaks during sleep} Dexamethazone: 0.3 mg or 0.25 mg/ other evening Prednisone: 3 mgAdrenal hyperplasia: higher dosesEffects: 1. No cortisol suppression 2. No Cushingoid side effects
![Page 56: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/56.jpg)
III. Antiandrogens: 1. Spironolactone (Aldactone)
Dose: 100-200 mg/d remission: dec dose to 25-50 mg100-200 mg/d from D1-D21Mechanism : on receptor ovary & adrenalsLiver kidney
![Page 57: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/57.jpg)
Side effects: minimal. Mens irregularities, mastalgia, feminization of male fetus, transient diuresis, hyperkalemia, ?carcinogenic Use with OCP: 1. Dramatic effect, but not impressively better 2. Prevent feminization of male fetus 3. Regular menstruation Effects: maximal by 6mo Cessation : relapse
![Page 58: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/58.jpg)
2. Cyproterone acetate (androcure)
Dose: 50-100 mg from D5 to D15 & EE2: 30-50 ug from D5 to D25. Dec dose after remissionMechanism: on receptors Progestational effectWeak corticosteroid effect
![Page 59: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/59.jpg)
Side effects: mens irregularities, mastalgia, feminization of male fetus, loss of libido, fatigue, edema, weight gain, decrease HDLP & cholesterol, glucose intolerance.Use with EE2 or OCPsEffects: maximal by 3mo improvement in 60-90% Cessation: relapse
![Page 60: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/60.jpg)
3. Flutamide (Eulexin)
Indication: under tertiary center supervision
Severe cases
Failure of spironolactone & OCPs
Dose:
250 - 500 mg/d
Mechanism:
antiandrogen.
![Page 61: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/61.jpg)
Side effects:
dryness of the skin, increase appetite
hepatotoxicity, expensive.
It is unsuitable for treatment of hirsuitism (Speroff, 2005)
Use with OCPs:
1. Add benefit 2. Avoid block androgen receptors in male fetus.
Effects:
Similar or better than Spironolactone
![Page 62: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/62.jpg)
IV. 5 alpha reductase inhibitors
Finasteride (Proscar)
Indication: under tertiary center supervision.
Severe cases
Mode of action:
Inhibit 5 alpha reductase activity: blocking conversion of T to DHT.
Dose:
2.5 - 5 mg /d
![Page 63: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/63.jpg)
Side effects:
very minimal. Teratogenic
Use with OCPs:
To avoid risk on male fetus & added benefits.
Effects:
Flutamide or Spironolactone is more effective
![Page 64: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/64.jpg)
V. Insulin sensitizer:
Metformin
•PCOS
IH: {insulin resistance} (Unluhizarci et al, 2004).
•1500 mg/d
•Dec serum insulin & T. Dec F&G score (Kazerooni et al, 2003 ; Kelly & Gordon, 2003)
![Page 65: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/65.jpg)
• Metformin Vs Dianette (EE2: 35 ug + cyproterone acetate: 2 mg)
Dianette was more effective (Harborne et al, 2003).
![Page 66: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/66.jpg)
•Cyprotrone acetate was compared to (spironolactone, flutamide, finastride, GnRHa, Ketconazole): No differences in clinical outcomes (Cochrane library, 2003)
![Page 67: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/67.jpg)
•Spironolactone 100 mg/d is superior to finastride 5 mg/d & low dose cypr acetate 12.5 mg/d (first 10 days of the cycle) up to 12 months after the end of the treatment (Cochrane library, 2003)
![Page 68: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/68.jpg)
III. LocalSuppress hair growth: Eflornithine Hydochloride (Vaniqa)
Remove hair pigment: Bleaching
Temporary depilation: shaving, chemical depilators
Temporary epilation: plucking, waxing
Permanent removal: Electrolysis, Laser & intense pulsed light
![Page 69: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/69.jpg)
1. Suppress hair growth: Eflornithine 13.9% (Vaniqa) cream
•inhibits ornithine decarboxylase (an enzyme in hair dermal papilla that is essential for hair growth).•Face, neck•Minimal s effects, can be used with other tt e.g. lasers, intense pulsed light, regrowth can take 2 ms •Must be continued indefinitely to prevent regrowthS effects: stinging, burning, tingling
![Page 70: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/70.jpg)
2. Bleaching (remove hair pigment)
•Hydrogen peroxide, often combined with amonia.
•Face, arms
•Hair lightens & softens, inexpensive
•Hair discoloration, skin irritation, Lack of effectiveness
![Page 71: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/71.jpg)
3. Temporary depilation (remove part of hair)
a. Shaving:
•All areas
•Inexpensive, effective & does not cause change in hair quality, quantity or texture.
•Daily need, skin irritation, quick regrowthfolliculitis, time consuming, beard stubble
![Page 72: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/72.jpg)
b. Chemical depilators:
•Break down & dissolve hair by hydrolysing disulhide bonds.
•Extremities, groin, face
•Quick, inexpensive, effective
•Regrowth in days, skin irritation
![Page 73: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/73.jpg)
4. Temporary epilation (remove the entire hair)
a. Plucking:
•Face, eyebrows, nipples, bikini area
•Effective for small amount, inexpensive, regrowth can take weeks
• Pain, skin irritation, postinflam pigmentation, folliculitis, slow, ingrown hairs, scarring
![Page 74: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/74.jpg)
b. Waxing: group plucking
•Face, eyebrows, groin, trunk, extremities
•Regrowth can take 6 weeks
•Pain, postinflam pigmentation, scarring, slow, expense, irritation, folliculitis
![Page 75: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/75.jpg)
5. Permanent removal (destruction of the dermal papilla)
a. Electrolysis:
•Needle is inserted into the hair follicle & a current is used to destroy the dermal papilla.
•All areas, usually the face
•May give permanent removal
•Pain, scarring, painful, repeat treatments needed, time consuming, expensive, pigmentation
![Page 76: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/76.jpg)
b. Laser & intense pulsed light
•Selective phototricholysis. A light source sufficient to penetrate to the follicular bulge & the papillae is directed at the hair by probe.
•All areas
•May give permanent hair reduction, efficient, painless
•Dark hair required, expensive, scarring, skin pigmentation, repeated treatments usually necessary
![Page 77: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/77.jpg)
IV. Surgery
•Tumor
•LOD
Discrepant & variable response.
A modest & sustained improvement in 25% (Amer et al, 2002).
![Page 78: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/78.jpg)
Guidelines for management1. The most desirable & effective tt is combination of OCP & antiandrogen.2. Response is relatively slow, & at least 6 mo are required to demonstrate an improvement. 3. TT should be continued for at least 1-2 yr.
![Page 79: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/79.jpg)
4 There is no evidence that one agent is better than another & choices should be governed by cost & side effects.5. The addition of GnRHa should be reserved for patients resistant to initial therapy.7. Local methods should be used but reserved until hormonal therapy has reduced the rate of hair growth i.e. after 6 mo.
![Page 80: Download](https://reader036.vdocuments.mx/reader036/viewer/2022070313/554953c1b4c90566498b4e47/html5/thumbnails/80.jpg)
Conclusion
2Tests: T & 17 Oh P
Drugs: COCs & Spironolactone
Years Treatment